Infectious Complications in Patients with Relapsed or Refractory (R/R) Non-Hodgkin's Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (BsAb) Mosunetuzumab

被引：2
|
作者：
Shahid, Zainab [1 ,2 ]
Okwali, Michelle [3 ]
Joseph, Ashlee [4 ]
Seo, Susan K. [2 ,5 ]
Lue, Jennifer Kimberly [4 ]
Boardman, Alexander P. [3 ]
Caron, Philip [3 ]
David, Kevin A. [3 ]
Epstein-Peterson, Zachary D. [3 ]
Ghione, Paola [4 ]
Hamlin, Paul A. [3 ]
Horwitz, Steven M. [4 ]
Intlekofer, Andrew M. [3 ]
Johnson, William [4 ]
Kumar, Anita [6 ]
Moskowitz, Alison [4 ]
Noy, Ariela [3 ]
Owens, Colette [3 ]
Palomba, Maria Lia [3 ]
Stuver, Robert [4 ]
Torka, Pallawi [3 ]
Vardhana, Santosha A. [3 ]
Zelenetz, Andrew D. [3 ]
Salles, Gilles [3 ]
Falchi, Lorenzo [3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Infect Dis Serv, New York, NY USA
[2] Weill Cornell Med, Dept Med, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Mem Sloan Kettering Canc Ctr, Dept Med, Infect Dis Serv, New York, NY USA
[6] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, Short Hills, NJ USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187911
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma
    Bender, Brendan
    Li, Chi-Chung
    Marchand, Mathilde
    Turner, David C.
    Li, Feifei
    Vadhavkar, Shweta
    Wang, Bei
    Deng, Rong
    Lu, James
    Jin, Jin
    Li, Chunze
    Yin, Shen
    Wei, Michael
    Chanu, Pascal
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (06):
  • [22] Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
    Lim, Tara L.
    Watts, Justn M.
    Mims, Alice S.
    Patel, Prapti
    Shami, Paul J.
    Cull, Elizabeth H.
    Cogle, Christopher R.
    Lee, Cynthia
    Uckun, Faith
    BLOOD, 2021, 138
  • [23] Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study
    Bartlett, Nancy L.
    Dickinson, Michael
    Hutchings, Martin
    Carlo-Stella, Carmelo
    Wu, Shang-Ju
    Leppa, Sirpa
    Trneny, Marek
    Corradini, Paolo
    Offner, Fritz
    Mulvihill, Estefania
    Bottos, Alessia
    Chohan, Saibah
    Baumlin, Pauline
    Relf, James
    Lundberg, Linda
    Bachy, Emmanuel
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study
    Kamdar, Manali
    Augustson, Bradley
    Rok, Young
    Edwards, James
    Hertzberg, Mark
    Johnston, Amanda
    Kim, Jin Seok
    Kroschinsky, Frank P.
    Smith, Sonali M.
    Stevens, Don A.
    Monnet, Annabelle
    Zhao, Ye
    Nouet, Yann
    Marinova, Viktoriya
    BLOOD, 2020, 136
  • [25] a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
    Maddocks, Kami J.
    Cohen, Jonathon B.
    Huang, Ying
    Christian, Beth A.
    Benson, Don M.
    Jones, Jeffrey
    Flowers, Christopher
    Heffner, Leonard T.
    Jenkins, Cynthia
    Sexton, Jennfer
    Neal, Alison
    Kives, Melissa
    Blum, Kristie A.
    BLOOD, 2016, 128 (22)
  • [26] Phase I study of CC-90011 in patients with advanced solid tumours (STs) and relapsed/refractory non-hodgkin lymphoma (R/R NHL)
    Hollebecque, A.
    de Bono, J. S.
    Salvagni, S.
    Plummer, R.
    Isambert, N.
    Niccoli, P.
    Capdevila, J.
    Curigliano, G.
    Moreno, V.
    De Braud, F. G. M.
    Lopez-Brea, M.
    Martin-Romano, P.
    Baudin, E.
    Arias, M.
    de Alvaro, J.
    Parra-Palau, J.
    Sanchez Perez, T.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Clofarabine (CLO) Has Single Agent Activity in Relapsed and Refractory Non-Hodgkin Lymphoma (NHL) Including Rituximab (R)-Refractory Patients (pts)
    Nabhan, Chadi
    Bitran, Jacob David
    Fried, Walter
    Galvez, Angel G.
    Magid, Laura
    Tolzien, Kathy
    Dewey, Wendy
    Venugopal, Parameswaran
    BLOOD, 2009, 114 (22) : 380 - 380
  • [28] Real-Life Experience with Lenalidomide Plus Anti-CD20 Antibodies for the Treatment of Patients (pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
    Cassanello, Giulio
    Rivas-Delgado, Alfredo
    De Abia, Alejandro Luna
    Corona, Magdalena
    Luttwak, Efrat
    Okwali, Michelle
    Isgor, Irem
    Galera, Pallavi
    Boardman, Alexander P.
    Caron, Philip
    David, Kevin A.
    Epstein-Peterson, Zachary D.
    Ghione, Paola
    Hamlin, Paul A.
    Lue, Jennifer Kimberly
    Horwitz, Steven M.
    Intlekofer, Andrew M.
    Johnson, William
    Kumar, Anita
    Moskowitz, Alison
    Noy, Ariela
    Owens, Colette
    Palomba, Maria Lia
    Stuver, Robert
    Torka, Pallawi
    Vardhana, Santosha A.
    Zelenetz, Andrew D.
    Salles, Gilles
    Falchi, Lorenzo
    BLOOD, 2023, 142
  • [29] Safety and efficacy of a novel anti-CD20/CD19 bispecific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).
    Liang, Aibin
    Zhou, Lili
    Li, Ping
    Yu, Wenjuan
    Yang, Min
    Xu, Yangyang
    Ye, Shiguang
    Zhu, Judy
    Huang, Jiaqi
    Zhang, Yan
    Li, Lanfang
    Zhao, Jing
    Li, Jing
    Zheng, Chengxiao
    Zhu, Kevin
    Lan, Liping
    Zhang, Huilai
    Zhou, Daobin
    Yao, Yihong
    Jin, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Activity of R-DHAOX regimen in patients (pts) affected by relapsed/resistant non-Hodgkin's lymphoma (NHL).
    Berretta, M
    Rupolo, M
    Michieli, M
    Spina, M
    Tirelli, U
    BLOOD, 2003, 102 (11) : 291B - 291B
12345